NCT05504317 - A Study of AK111 in Subjects With Moderate-to-severe Plaque Psoriasis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 28, 2020

Primary Completion Date

March 2, 2021

Study Completion Date

March 2, 2021

Conditions

Psoriasis

Interventions

DRUG

AK111

Subjects will receive one of four escalated doses of AK111 (75mg/150mg/300mg/450mg) injection subcutaneously.

DRUG

Placebo

Subjects will receive corresponding dose of placebo injection subcutaneously.

Trial Locations (2)

AkesoBio Investigative Site 1002, Bengbu

AkesoBio Investigative Site 1001, Beijing